Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis
, , , , , e
19 giu 2024
INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 19 giu 2024
Pagine: 90 - 96
DOI: https://doi.org/10.2478/pneum-2024-0014
Parole chiave
© 2023 Victoria Țau et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Țau, Victoria
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Antal, Andreea Zabară
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”Iași, Romania
Antohi, Paula Vasilache
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Stoian, Ioana Adelina
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”Iași, Romania
Pintilie, Adriana Loredana
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Trofor, Antigona Carmen
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”Iași, Romania
Crișan-Dabija, Radu Adrian
Clinical Hospital of Pulmonary Diseases IașiIasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”Iași, Romania